Copyright Reports & Markets. All rights reserved.

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Market Overview

    • 1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Exenatied
      • 1.2.2 Liraglutide
      • 1.2.3 Lixisenatide
      • 1.2.4 Albiglutide
      • 1.2.5 Dulaglutide
    • 1.3 Market Analysis by Applications
      • 1.3.1 Hospital
      • 1.3.2 Pharmacy
      • 1.3.3 Other
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2014-2024)
        • 1.4.1.2 Canada Market States and Outlook (2014-2024)
        • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2014-2024)
        • 1.4.2.2 France Market States and Outlook (2014-2024)
        • 1.4.2.3 UK Market States and Outlook (2014-2024)
        • 1.4.2.4 Russia Market States and Outlook (2014-2024)
        • 1.4.2.5 Italy Market States and Outlook (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2014-2024)
        • 1.4.3.2 Japan Market States and Outlook (2014-2024)
        • 1.4.3.3 Korea Market States and Outlook (2014-2024)
        • 1.4.3.4 India Market States and Outlook (2014-2024)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
        • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
        • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
        • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 Novo Nordisk
      • 2.1.1 Business Overview
      • 2.1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 AstraZeneca
      • 2.2.1 Business Overview
      • 2.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Eli Lilly
      • 2.3.1 Business Overview
      • 2.3.2 Glucagon Like Peptide-1 (GLP-1) Agonists Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 GSK
      • 2.4.1 Business Overview
      • 2.4.2 Glucagon Like Peptide-1 (GLP-1) Agonists Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Sanofi
      • 2.5.1 Business Overview
      • 2.5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Bristol-Myers Squibb
      • 2.6.1 Business Overview
      • 2.6.2 Glucagon Like Peptide-1 (GLP-1) Agonists Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Amylin
      • 2.7.1 Business Overview
      • 2.7.2 Glucagon Like Peptide-1 (GLP-1) Agonists Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

    • 3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Manufacturer (2017-2018)
    • 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Manufacturer (2017-2018)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer Market Share in 2018
      • 3.3.2 Top 6 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer Market Share in 2018
    • 3.4 Market Competition Trend

    4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis by Regions

    • 4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Regions (2014-2019)
      • 4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Regions (2014-2019)
    • 4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 4.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 4.5 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)

    5 North America Glucagon Like Peptide-1 (GLP-1) Agonists by Country

    • 5.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
      • 5.1.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2014-2019)
      • 5.1.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2014-2019)
    • 5.2 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 5.3 Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 5.4 Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)

    6 Europe Glucagon Like Peptide-1 (GLP-1) Agonists by Country

    • 6.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
      • 6.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2014-2019)
      • 6.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2014-2019)
    • 6.2 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 6.3 UK Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 6.4 France Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 6.5 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 6.6 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)

    7 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists by Country

    • 7.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
      • 7.1.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2014-2019)
      • 7.1.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2014-2019)
    • 7.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 7.3 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 7.4 Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 7.5 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)

    8 South America Glucagon Like Peptide-1 (GLP-1) Agonists by Country

    • 8.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
      • 8.1.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2014-2019)
      • 8.1.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2014-2019)
    • 8.2 Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 8.3 Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 8.4 Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)

    9 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists by Countries

    • 9.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
      • 9.1.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2014-2019)
      • 9.1.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2014-2019)
    • 9.2 Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 9.3 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 9.4 Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 9.5 Nigeria Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)
    • 9.6 South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2014-2019)

    10 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Segment by Type

    • 10.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Type (2014-2019)
      • 10.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Type (2014-2019)
      • 10.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Type (2014-2019)
    • 10.2 Exenatied Sales Growth and Price
      • 10.2.1 Global Exenatied Sales Growth (2014-2019)
      • 10.2.2 Global Exenatied Price (2014-2019)
    • 10.3 Liraglutide Sales Growth and Price
      • 10.3.1 Global Liraglutide Sales Growth (2014-2019)
      • 10.3.2 Global Liraglutide Price (2014-2019)
    • 10.4 Lixisenatide Sales Growth and Price
      • 10.4.1 Global Lixisenatide Sales Growth (2014-2019)
      • 10.4.2 Global Lixisenatide Price (2014-2019)
    • 10.5 Albiglutide Sales Growth and Price
      • 10.5.1 Global Albiglutide Sales Growth (2014-2019)
      • 10.5.2 Global Albiglutide Price (2014-2019)
    • 10.6 Dulaglutide Sales Growth and Price
      • 10.6.1 Global Dulaglutide Sales Growth (2014-2019)
      • 10.6.2 Global Dulaglutide Price (2014-2019)

    11 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Segment by Application

    • 11.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2014-2019)
    • 11.2 Hospital Sales Growth (2014-2019)
    • 11.3 Pharmacy Sales Growth (2014-2019)
    • 11.4 Other Sales Growth (2014-2019)

    12 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2019-2024)

    • 12.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Growth Rate (2019-2024)
    • 12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by Regions (2019-2024)
      • 12.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2019-2024)
      • 12.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2019-2024)
      • 12.2.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2019-2024)
      • 12.2.4 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2019-2024)
      • 12.2.5 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2019-2024)
    • 12.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by Type (2019-2024)
      • 12.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2019-2024)
      • 12.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Type (2019-2024)
    • 12.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by Application (2019-2024)
      • 12.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2019-2024)
      • 12.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Application (2019-2024)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

      Scope of the Report:
      United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
      The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.
      Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
      The worldwide market for Glucagon Like Peptide-1 (GLP-1) Agonists is expected to grow at a CAGR of roughly 14.3% over the next five years, will reach 11700 million US$ in 2024, from 5240 million US$ in 2019, according to a new GIR (Global Info Research) study.
      This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

      Market Segment by Manufacturers, this report covers
      Novo Nordisk
      AstraZeneca
      Eli Lilly
      GSK
      Sanofi
      Bristol-Myers Squibb
      Amylin

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia etc.)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Exenatied
      Liraglutide
      Lixisenatide
      Albiglutide
      Dulaglutide

      Market Segment by Applications, can be divided into
      Hospital
      Pharmacy
      Other

      The content of the study subjects, includes a total of 15 chapters:
      Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market opportunities, market driving force and market risks.
      Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales, revenue and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists in 2017 and 2018.
      Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
      Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
      Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
      Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
      Chapter 12, Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
      Chapter 13, 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion, appendix and data source.

      Buy now